Fallout can be an opportunity when both makers and service providers see the need to collaborate to solve China's acute and changing regulatory demand.
If there is only one thing certain about China is there is no certainty.
The year of 2016 is possibly remembered by many vaccines makers in China as a year of disruptions.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.
LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.
